Close Menu

NEW YORK – Immunomedics said on Monday that its antibody-drug conjugate sacituzumab govitecan-hziy (Trodelvy) met its primary endpoint of progression-free survival in the confirmatory Phase III ASCENT trial of metastatic triple-negative breast cancer patients who did not have brain metastases and had received at least two prior therapies.  

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
08
Sponsored by
Roche

This webinar will discuss a single-center prospective interventional study that evaluated the success of a targeted therapy selected by profiling of ctDNA and tissue in patients with advanced and refractory carcinoma.